Skip to main content
Clinical Trials/IRCT20200408046990N4
IRCT20200408046990N4
Recruiting
Phase 3

Evaluation of the effect of oral formulation prepared from extract of pomegranate for treatment of benign prostate hyperplasia: A triple blind randomized clinical trial

Mashhad University of Medical Sciences0 sites40 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
benign prostate hyperplasia.
Sponsor
Mashhad University of Medical Sciences
Enrollment
40
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • age between 50\-80 years
  • Mild to moderate clinical diagnisis of BPH (patient has lower urinary (based on international prostate symptom score (IPSS)\<18\)

Exclusion Criteria

  • simultaneous use of BPH medications except tamsulosin
  • use of supplements which existing in BPH such as saw palmetto , vitamin E and Quercetin vitamins
  • having prostate or bladder cancer
  • history of prostate surgery
  • PSA\>4mg/ml
  • Post void residue (PVR)\=200 ml
  • history of allergy to pomegranate and its derivatives
  • use of medications with considerable metabolism through Cytochrome 3A4

Outcomes

Primary Outcomes

Not specified

Similar Trials